key: cord-0839048-chregbgp authors: Micocci, Massimo; Gordon, Adam L; Seo, Mikyung Kelly; Allen, A Joy; Davies, Kerrie; Lasserson, Dan; Thompson, Carl; Spilsbury, Karen; Akrill, Cyd; Heath, Ros; Astle, Anita; Sharpe, Claire; Perera, Rafael; Hayward, Gail; Buckle, Peter title: Is Point-of-Care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of a Point-of-Care Polymerase Chain Reaction test for SARS-COV-2 date: 2021-04-21 journal: Age Ageing DOI: 10.1093/ageing/afab072 sha: 2faf8d4f1376ea89456cd01a3d42b9df9584932d doc_id: 839048 cord_uid: chregbgp INTRODUCTION: Reliable rapid testing for COVID-19 is needed in care homes to reduce the risk of outbreaks and enable timely care. This study aimed to examine the usability and test performance of a point of care polymerase chain reaction (PCR) test for detection of SARS-COV2 (POCKITTM Central) in care homes. METHODS: POCKITTM Central was evaluated in a purposeful sample of four UK care homes. Test agreement with laboratory real-time PCR and usability and use errors were assessed. RESULTS: No significant usability-related hazards emerged, and the sources of error identified were found to be amendable with minor changes in training or test workflow. POCKITTM Central has acceptable sensitivity and specificity based on RT-PCR as the reference standard, especially for symptomatic cases. Asymptomatic specimens showed 83.3% (95% CI: 35.9%-99.6%) positive agreement and 98.7% negative agreement (95% CI: 96.2%-99.7%), with overall prevalence and bias-adjusted kappa (PABAK) of 0.965 (95% CI: 0.932– 0.999). Symptomatic specimens showed 100% (95% CI: 2.5%-100%) positive agreement and 100% negative agreement (95% CI: 85.8%-100%), with overall PABAK of 1. Recommendations are provided to mitigate the frequency of occurrence of the residual use errors observed. Integration pathways were discussed to identify opportunities and limitations of adopting POCKIT™ Central for screening and diagnostic testing purposes. CONCLUSION: Point-of-care PCR testing in care homes can be considered with appropriate preparatory steps and safeguards. Further diagnostic accuracy evaluations and in-service evaluation studies should be conducted, if the test is to be implemented more widely, to build greater certainty on this initial exploratory analysis. Care home residents have been amongst the worst affected by the COVID-19 pandemic [1] . In England and Wales, the Office of National Statistics estimates that care homes experienced 21,344 excess deaths due to COVID-19 during the first 10 months of the pandemic [2]. As the pandemic has continued, attention has turned to how SARS-COV-2 testing might help better protect residents from COVID-19 outbreaks, whilst enabling continuity of service provision and promoting quality of life for residents, by restoring routine practices such as family visiting [3] . Point-of-care testing (POCT) describes tests that take place close to the care setting [4, 5] . We have previously described possible roles for POCT for COVID-19 in screening asymptomatic residents and staff, and diagnostic testing for symptomatic residents and staff [6] For both use cases, POCT could reduce administrative burden and test turnaround times, and reduce the chances of COVID-19 outbreaks through earlier quarantine of positive cases. The "real world" effectiveness of POCT in care homes is a function of the technical properties of the test (established in laboratory conditions where certainty and parameters are controlled) and its performance in the conditions of uncertainty that exist in homes, such as residents with complex multimorbidity, variation in testing behaviours in staff, variable infection control processes and implementation. POCT should take account of how testing can integrate into existing measures of transmission control, and the complexity involved in preparing for testing, conducting testing, and interpreting and responding to results. Very little is known as to how well the POCTs can be integrated into care home settings and their readiness for adoption among potential users. If these POCTs are implemented into settings that they have not been designed for there is an inherent risk that the operator will execute the test improperly, use it in the way not intended, or even reject the test for lack of perceived benefits. As part of (author reference) [7], our study aim was to evaluate a point-of-care polymerase chain reaction (PCR) test for detection of SARS-COV2 in the UK care home setting. Our primary objective was to rapidly explore the usability and readiness of the technology for use in real-world settings, to scope usability requirements, prioritise areas of deployment, and to identify any possible safety concerns and sources of error to be further investigated and mitigated. A secondary objective was to evaluate the agreement between results from the POC test with the laboratory-based Reverse Transcriptase-PCR (RT-PCR), the current benchmark standard for care homes. The technology being evaluated was the POCKIT™ Central Nucleic Acid Analyzer (POCKIT™ Central). This is a benchtop molecular detection system, integrating magnetic bead-based nucleic acid extraction, fluorescence-based insulated isothermal PCR (iiPCR) amplification/detection, and liquid handling technologies to offer a walk-away protocol for nucleic acid detection. The machine can run tests on up to eight specimens at once. Results are displayed on the monitor in less than 1.5 hours. POCKIT™ Central machines were delivered directly to care homes, and training provided, by the manufacturer. Only staff members who received formal training were permitted to use the machine This study consists of two activities: 1. Scoping usability and use errors. 2. Test agreement with laboratory RT-PCR. No formal power calculation was undertaken. Further evaluation of diagnostic accuracy is being conducted in other parts of the CONDOR platform. The CONDOR study has recruited 28 care homes, caring for more than 1490 residents, to our testing platform. These were recruited through publicity in a national care home WhatsApp COVID-19 peer support group [8], public-facing social media and the national care home umbrella organisations Care England and the National Care Forum. The care home database is active, and we continue to recruit. It includes nursing and residential homes; corporate chain, independent and third-sector providers; and bed capacity ranging from 20+ -350+ in each home. From this, we selected a purposive sample of four care homes (Table 1) , comprising two care homes with nursing and two care homes without nursing (also known as nursing and residential homes respectively), from two regions of the UK, two independents and two small chains, to ensure we maximised our ability to account for differences in staff training, and organisational configuration, that might impact on the implementation or use of a point-of-care test. We chose the number of participants based upon the need to understand workflows around staff and resident routine testing, whilst capturing errors that might occur on repeated use of the machine, by different staff members, on different days, under different circumstances. To scope usability areas and potential sources of error, semi-structured interviews were conducted with key stakeholders (Table 1 ). These interviews also enabled further insights regarding potential operational and pathway integration of the new test. Participants were directly involved with trialling POCKIT TM Central in care homes and had experience in using the device. Stakeholders were interviewed individually and remotely by a researcher in Human Factors (XX author initials) at the end of the trial. In one instance, for reasons of practicality, two interviewees who worked together were interviewed together. Interviews were semi-structured and lasted 30-60 minutes; they were audio and video recorded, with the permission of the participants. Interview schedules focused on the manufacturer's instructions for use, how POCKIT TM Central might be integrated into the diagnostic pathway, the testing strategy and the clinical decision making based on positive and negative results. Participants were then prompted to explore potential usability issues in the use of POCKIT TM Central (including clarity of test results, potential hazards and the disposal procedure). We chose to focus primarily on routine staff testing. This is currently conducted weekly, and results from PCR laboratory tests do not always arrive within seven days. A growing body of evidence suggests that asymptomatic transmission from staff is likely to be one of the most important factors in care home outbreaks [9] . We estimated that conducting 65 tests in each of the four care homes would allow enough repetition of the testing procedure to capture variability in practice between people and over time. The breakdown of tests between the different groups were: 35 routine staff tests; 15 routine resident tests; and 15 tests for resident or staff who had become symptomatic. Nasopharyngeal swabs were taken by care home staff, adhering to standard testing procedures recommended by the government [10], using government-issued testing kits. Use of the POCKIT™ Central device followed a Standard Operating Procedure (see Appendix I) written by laboratory staff after risk assessing the extent of viral inactivation in the sample buffer. Once the testing swab had been inserted into the viral transport medium, 200 L was transferred into the POCKIT™ Central testing well by the care home staff member using a pre-set Gilson pipette and sterile filter tips. The remainder of the specimen was sent for formal laboratory testing as usual. Care home staff documented testing results from the POCKIT™ Central device using a results log, adding formal laboratory results when these returned. Only anonymised data were seen by the research team. Samples were not blinded at any stage. All test results, including equivocal results and failures, were reported as per US Food and Drug Administration (FDA) guidance [11] . We calculated positive and negative agreement of POCKIT™ Central with the formal laboratory RT-PCR results, the (Cohen) kappa, the Brennan and Prediger statistic (equal to the prevalence and biased adjusted kappa (PABAK)) as well as prevalence based on laboratory RT-PCR results, with their associated 95% confidence intervals. The primary analysis was based on valid results for all tests stratified by symptomatic/asymptomatic participants. These calculations were carried out in Stata/SE 16.1 using: diagt and kappaetc. We also carried out a sensitivity analysis including all POCKIT™ Central equivocal results and test failures in our calculations described above. The Human Factors experts reviewed all potential critical issues in the main operation tasks of POCKIT TM Central that could lead to errors and hazards affecting the test operators and the care home residents. Instructions for use and a video demonstration were analysed to highlight the expected source of errors. Four operation tasks and potential risks of use and errors were identified and are outlined in figure 1 . Each task and the probability of occurrence of these potential errors were discussed with interview participants. The overall experience with testing equipment was positive. Using the device did not cause excessive cognitive workload as users easily remembered the required steps. Handling components and inserting them into the correct location was not problematic and did not lead to errors. The test activationwhich included navigating the digital interface -was considered "easy to manage" (CH2-CH3) and staff members appreciated the presence of prompts and a home button for better control of the process (CH1). No results misinterpretation was observed. Results were correctly recorded. Each test was linked to a unique ID and the data automatically saved for retrieval. The list of observed errors and unexpected situations have been divided based on the four operative procedure's stages. Relevant quotes from participants and mitigation strategies to reduce the occurrence of errors are reported (Table 2) . Quotes are selected for their relevance to inform key usability aspects and to corroborate findings. In total 278 tests were run. Tests were conducted on 252 asymptomatic participants (176 staff and 76 residents) and 26 symptomatic participants (13 staff and 13 residents) ( Table 3 and Appendix II Table A1 stratified by staff/residents). Formal laboratory results were indeterminate for five specimens. POCKIT TM Central results were not available for 17 tests; one was a sporadic error, the remaining 16 were compromised by sealing glue left on top of the POCKIT TM Central cartridge. This was an avoidable error, which is described in detail above. A Standard for Reporting of Diagnostic Accuracy Studies (STARD) Flow diagram is shown in Figure 2 . Thus, agreement analysis was conducted on 256 specimens: 177 from staff, 164 asymptomatic, and 13 symptomatic; 79 from residents, 67 asymptomatic and 12 symptomatic. Estimated prevalence data, positive and negative agreement, and kappa and PABAK results for asymptomatic and symptomatic participants are shown in Table 4 . Equivalent statistics based on including all POCKIT™ Central equivocal and failures are reported in Appendix II Table A2 . This paper reports the first exploratory in-context evaluation of point-of-care (POC) PCR for SARS-COV-2 in the care home setting. We found no significant hazards and the sources of error identified were amenable to relatively minor changes in training or test workflow. Therefore, adopting POCKIT TM Central in a care home setting can be considered safe and feasible with appropriate preparatory steps and safeguards in place. The positive and negative agreement reported in this study can be compared to the measures of sensitivity and specificity based on RT-PCR as the reference standard. The estimates presented here for POCKIT™ Central were acceptable, particularly for symptomatic participants. Overall, participants reacted enthusiastically to the possibility of implementing their care home's testing capability; the ability to promptly react on results, especially if positive, has a great effect on staff confidence and it might limit the detrimental effects of unnecessary isolations of residents. As part of the effort to gradually re-open care homes to planned visits, a POC test will contribute to the opportunity to screen care home visitors for COVID-19. However, the specific workflow or safety issues associated with testing visitors were not investigated in this study; given the atypicality of virus presentation and still unclear relations between viral load and shedding, infection and infectiousness [12] , results from POCT should be used in combination, and not as a substitute for infection homes. If such technology is to be widely deployed, then CE marks will have to take account of the competency mix of care home staff. A key limitation of this study, is that it was not statistically powered to evaluate diagnostic accuracy. The low number of positives seen explains the wide confidence intervals reported for all estimates, particularly positive agreement. We report several measures of agreement stratified by symptomatic/asymptomatic to reflect potential different use of these tests. Office of National Statistics. Number of deaths in care home notified to the Care Quality Commission COVID-19: Managing the COVID-19 pandemic in care homes for older people Point-of-care testing: an introduction Point-of-Care Devices for Pathogen Detections: The Three Most Important Factors to Realize towards Commercialization SEeking AnsweRs for Care Homes during the COVID-19 pandemic (COVID SEARCH) Vivaldi 1: Coronavirus (COVID-19) care homes study report Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests -Guidance for Industry and FDA Staff Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing date last accessed) 14. National Institute for Health and Care Excellence. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests The authors would like to thank care home managers and staff members who took part in the study and members of the CONDOR platform for their comments: Mr Graham Prestwich and Ms Val Tate.